Evidence map›Paper›PMID 42806051›Full record

ArticleLeukemia2026

Two cases of an imatinib-sensitive PRKG2::PDGFRA-positive chronic myeloid neoplasm with basophilia.

Johannes Lübke, Olaposi Yomade, Manja Meggendorfer, Jan-Hendrik Kozik, Marietta Truger, Wencke Walter, Stephan Hutter, Uwe Martens, Martina Rudelius, Nicole Naumann and 15 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Johannes LübkeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0767-1504
Olaposi YomadeKlinik für Innere Medizin II, Universitätsklinikum Jena; Comprehensive Cancer Center Central Germany - Campus Jena, Jena, Germany.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-9038-3265
Jan-Hendrik KozikMLL Munich Leukemia Laboratory, Munich, Germany.
Marietta TrugerMLL Munich Leukemia Laboratory, Munich, Germany.
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-5083-9838
Stephan HutterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0003-2432-8898
Uwe MartensKlinik für Innere Medizin III, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.ORCID http://orcid.org/0000-0001-7999-4359
Martina RudeliusDepartment of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Matthew SalmonFaculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0003-0647-5501
Carl CrodelKlinik für Innere Medizin II, Universitätsklinikum Jena; Comprehensive Cancer Center Central Germany - Campus Jena, Jena, Germany.
Jenny RinkeKlinik für Innere Medizin II, Universitätsklinikum Jena; Comprehensive Cancer Center Central Germany - Campus Jena, Jena, Germany.ORCID http://orcid.org/0009-0006-7791-6561
Hans-Peter HornyDepartment of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Florian H HeidelDepartment of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany.ORCID http://orcid.org/0000-0003-2438-1955
Jan Hinrich BräsenInstitute of Pathology, Hannover Medical School (MHH), Hannover, Germany.
Hans-H KreipeInstitute of Pathology, Hannover Medical School (MHH), Hannover, Germany.ORCID http://orcid.org/0000-0003-0708-1790
Georgia MetzgerothDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Nicholas C P CrossFaculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-5481-2555
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0003-0196-2837
Juliana SchwaabDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Andreas HochhausKlinik für Innere Medizin II, Universitätsklinikum Jena; Comprehensive Cancer Center Central Germany - Campus Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-0626-0834
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. andreas.reiter@medma.uni-heidelberg.de.

Funding

Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2023.120.1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42806051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.